Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be ≥ 3 months and ≤30 years of age.~* Stratum A: Non-Malignant Diseases, including:~  * Bone Marrow Failure Syndromes~ * Hemoglobinopathies or transfusion-dependent red blood cell (RBC) defects~ * Congenital Immunodeficiencies~ * Metabolic Diseases known to be treatable with Hematopoietic cell transplantation (HCT) (e.g. Hurler's)~ * Other Bone Marrow Stem Cell Defects (e.g. Osteopetrosis)~ * Severe Immune Dysregulation / Autoimmune Syndromes with at least transient prior response to immunosuppressive therapy~* Stratum B: Myeloid Malignancies, including:~  * acute myeloid leukemia (AML), in greater than first clinical remission, or in CR1 but with detectable disease (≥0.1% Blasts by minimal residual disease (MRD) or Flow, or Positive Cytogenetics), or in CR1 but with a matched sibling Umbilical cord blood (UCB) donor.~ * Myelodysplastic syndromes (MDS)~ * Juvenile myelomonocytic leukemia (JMML)~ * Chronic myeloid leukemia (CML), with detectable disease by polymerase chain reaction (PCR)~* Patients must have a suitable donor based on the University of California, San Francisco (UCSF) Pediatric Bone Marrow Transplant (BMT) standard operating procedures (SOP). 10/10 (HLA-A, -B, -C, -DR, -DQ) matching will be done for related and adult unrelated donors; 8/8 (HLA-A, -B, -C, -DR) for umbilical cord blood donors. Patients with non-malignant diseases will generally be eligible only if they have a mismatched donor, or an accepted clinical reason to be considered high-risk for rejection.~* Liver transaminases (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) and Direct Bilirubin less than twice the upper limit of normal within 2 weeks of admission.~* Cardiac Shortening Fraction ≥27% within 4 weeks of admission.~* Creatinine clearance by Schwartz formula, glomerular filtration rate (GFR) or 24 hr urine collection ≥50 cc/min/1.73 m2, within 4 weeks of admission.~* Pulmonary diffusion capacity ≥50% of predicted corrected for anemia/lung volume within 4 weeks of admission. If unable to do Pulmonary function testing(PFTs), then no active lung disease by chest x-ray (CXR) and/or oxygen (O2) Saturation ≥90% on room air.~Exclusion Criteria:~* Fanconi Anemia~* Dyskeratosis Congenita~* A known syndrome with increased sensitivity to radiation or alkylating agents~* Severe Combined Immunodeficiency Disease eligible for a non-myeloablative HCT Trial~* A mismatched donor for whom ex vivo T-cell depletion of the donor stem cells is planned

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Myeloid Malignancies (Type: EXPERIMENTAL): None
- Patients with Non-Malignancies (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy